Openbookopenbook
Equity
IDYA
+0.0 · +0.00%
USD · NASDAQ

Ideaya Biosciences Inc(IDYA) Stock Analysis | Healthcare

USD --+0.00%
Reward56Moderate
Risk29Low
75%Data
Thin -75% profit margin · Revenue growing 55% YoY
Profitless Growth
Market Cap:3.83Bn
ⓘ
Reward Rating
56
Moderate
Reward Assessment
75% data coverage
Bottom 50% of stocksView factors
ⓘ
Risk Rating
29
Low
Risk Assessment
4 metrics flaggedView details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on IDYA to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
New listing — limited trading history
Fundamental and analyst data are available for IDYA, but momentum and volatility metrics will develop as more trading history accumulates (0 trading sessions so far).
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: $52.15.

What is Ideaya Biosciences Inc?

, a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States.

IDYA · Verdict

Solid reward · low risk

IDYA stands out on balance sheet and valuation, but watch the cash flow signal.

Based on 88% data coverage

IDYA · Verdict

What’s working & what to watch

Strengths 4

  • Balance sheet100/100

    Current ratio 11.34

  • Valuation78/100

    P/E 4.6×

  • Growth76/100

    Rev +62.5% CAGR · earnings +27.5%

  • Volatility75/100

    Above average

Watchouts 2

  • Cash flow6/100

    -34% free-cash-flow margin

  • Profitability9/100

    -52% net margin · -16% ROE

Model-based scoring. For information only — not financial advice.

What is Ideaya Biosciences Inc?

, a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 3.83B.

Financial Highlights

Investment Breakdown

Growth
Revenue and earnings growing steadily, indicating improving operating performance.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Below-average volatility supports a steadier risk profile.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (56)

The scoring profile indicates moderate reward potential, with valuation and growth as the leading contributors. Risk indicators are low, suggesting a relatively contained downside profile.

For informational purposes only. Not financial advice.

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

GNNSFMid Cap / 3.8B market cap
Genscript Biotech Corporation
Compare
TLXMid Cap / 3.8B market cap
Telix Pharmaceuticals Limited
Compare
CPRXMid Cap / 3.9B market cap
Catalyst Pharmaceuticals Inc
Compare
Company Information
SectorHealthcare
IndustryBiotechnology
Market Cap3.83B
P/E RatioN/A
Dividend YieldN/A
Beta-0.091
Insider Activity
12M windowQuiet
Fewer than three real open-market insider trades in the last 12 months. Mechanical activity (option exercises, RSU vests) is excluded from the signal.
openbook

Stock research for UK and US investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.